Company News
Company News
Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
March 19, 2022
Vancouver, British Columbia, Canada – March 19, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities
March 15, 2022
Vancouver, British Columbia, Canada – March 15, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin
March 12, 2022
Successful Breakthrough of Biosynthetic Psilocybin Production Method Progressing Quickly
Vancouver, British Columbia, Canada – March 12, 2022 – Core One Labs...
Read more
Company News
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations
March 04, 2022
Vancouver, British Columbia, Canada – March 4, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the...
Read more
Company News
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
March 03, 2022
VANCOUVER, British Columbia, March 3, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core...
Read more
Company News
Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
February 21, 2022
Vancouver, British Columbia, Canada – February 21, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One”...
Read more